PHARMACEUTICAL DOSAGE FORM FOR ORAL ADMINISTRATION OF A BCL-2 FAMILY INHIBITOR

The invention relates to a pharmaceutical dosage form which comprises a solid dispersion product comprising N-(4-(4-((2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohex-1-en-1-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methyl) propyl)amino)-3-((trifluoromethyl)sulfonyl)...

Full description

Saved in:
Bibliographic Details
Main Authors Knobloch Martin, Packhaeuser Claudia, Liepold Bernd, Kostelac Drazen, Steiger Norbert
Format Patent
LanguageEnglish
Published 06.07.2017
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online AccessGet full text

Cover

Abstract The invention relates to a pharmaceutical dosage form which comprises a solid dispersion product comprising N-(4-(4-((2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohex-1-en-1-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methyl) propyl)amino)-3-((trifluoromethyl)sulfonyl)benzenesulfonamide or a salt, hydrate or solvate thereof, at least one pharmaceutically acceptable polymer, and at least one pharmaceutically acceptable solubilizer. The invention is further directed to processes for preparing the pharmaceutical dosage form and to use of the dosage form for treating proliferative disorders
AbstractList The invention relates to a pharmaceutical dosage form which comprises a solid dispersion product comprising N-(4-(4-((2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohex-1-en-1-yl)methyl)piperazin-1-yl)benzoyl)-4-(((1R)-3-(morpholin-4-yl)-1-((phenylsulfanyl)methyl) propyl)amino)-3-((trifluoromethyl)sulfonyl)benzenesulfonamide or a salt, hydrate or solvate thereof, at least one pharmaceutically acceptable polymer, and at least one pharmaceutically acceptable solubilizer. The invention is further directed to processes for preparing the pharmaceutical dosage form and to use of the dosage form for treating proliferative disorders
Author Liepold Bernd
Packhaeuser Claudia
Steiger Norbert
Kostelac Drazen
Knobloch Martin
Author_xml – fullname: Knobloch Martin
– fullname: Packhaeuser Claudia
– fullname: Liepold Bernd
– fullname: Kostelac Drazen
– fullname: Steiger Norbert
BookMark eNrjYmDJy89L5WTwC_BwDPJ1dHYNDfF0dvRRcPEPdnR3VXDzD_IFEQr-QUBBRxdfTz_P4JAgxxBPfz8FfzcFRwUnZx9dIwU3R19Pn0gFTz8PTyfPEP8gHgbWtMSc4lReKM3NoOzmGuLsoZtakB-fWlyQmJyal1oSHxpsZGBobmhhaWJk5mhoTJwqANCFMMw
ContentType Patent
DBID EVB
DatabaseName esp@cenet
DatabaseTitleList
Database_xml – sequence: 1
  dbid: EVB
  name: esp@cenet
  url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP
  sourceTypes: Open Access Repository
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Chemistry
Sciences
ExternalDocumentID US2017189426A1
GroupedDBID EVB
ID FETCH-epo_espacenet_US2017189426A13
IEDL.DBID EVB
IngestDate Fri Jul 19 12:48:07 EDT 2024
IsOpenAccess true
IsPeerReviewed false
IsScholarly false
Language English
LinkModel DirectLink
MergedId FETCHMERGED-epo_espacenet_US2017189426A13
Notes Application Number: US201715466673
OpenAccessLink https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20170706&DB=EPODOC&CC=US&NR=2017189426A1
ParticipantIDs epo_espacenet_US2017189426A1
PublicationCentury 2000
PublicationDate 20170706
PublicationDateYYYYMMDD 2017-07-06
PublicationDate_xml – month: 07
  year: 2017
  text: 20170706
  day: 06
PublicationDecade 2010
PublicationYear 2017
RelatedCompanies AbbVie Inc
RelatedCompanies_xml – name: AbbVie Inc
Score 3.0945961
Snippet The invention relates to a pharmaceutical dosage form which comprises a solid dispersion product comprising...
SourceID epo
SourceType Open Access Repository
SubjectTerms HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Title PHARMACEUTICAL DOSAGE FORM FOR ORAL ADMINISTRATION OF A BCL-2 FAMILY INHIBITOR
URI https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20170706&DB=EPODOC&locale=&CC=US&NR=2017189426A1
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dS8MwED_GFPVNp-J0SkDpW3HdsrZ7GNKmLa2sH3StzKfRdi0I0g1X8d_3Ejbd015CcoEjOfjl7nK5C8DToI9opnku6xWtZDosqJxlykge0Crj5rjWL7mj6Aeqm9LX-Wjegs9dLoyoE_ojiiMiogrEeyPO6_X_JZYl3lZunvMPJK1enGRiSVvvWNGQuSpZ5sSOQitkEmOTdCYFsZhT9DHqIwN9pSM0pDWOB_vN5Hkp632l4pzDcYT86uYCWmXdgVO2-3utAyf-NuSN3S36NpcQRK4R-waz04RXMSBWyONBBP04nzckjJFoWL4XePwrZH75REKHGMRkU3lAHMP3pu_EC1zP9JIwvoJHx06YK-PCFn9yWKSz_V0Mr6Fdr-ryBsi4LJVqWWn9gmaUarxolz5Ui2yJeCzGxagLvUOcbg9P38EZH4o3qmoP2s3Xd3mPmrjJH4QAfwHkFYT-
link.rule.ids 230,309,783,888,25576,76876
linkProvider European Patent Office
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3dS8MwED_GFOebTsWPqQGlb8V1y9rtYUibtjTaj9G1Mp9G27UgSDdcxX_fS9l0T3sJIQdHEvjlcrm7XwAee11EM01TeVjQQqb9jMpJogzkHi0ScR3XurlwFD1fdWL6MhvMGvC5rYWpeUJ_anJERFSGeK_q83r1_4hl1rmV66f0A4eWz3Y0NqWNd6xoqFyVTGNsTQIzYBJj43gq-WEtU4YjtEc6-koHeMnWBB6sN0PUpax2jYp9AocT1FdWp9DIyza02PbvtTYceZuQN3Y36FufgT9x9NDTmRVHgsWAmIGIBxH04zzRkCDEQd30uM_FV8ji8YkENtGJwVy5R2zd4-474b7DDR4F4Tk82FbEHBknNv_bh3k83V1F_wKa5bLML4GM8lwpFoXWzWhCqSZIu4Z9NUsWiMdslA2uoLNP0_V-8T20nMhz5y73X2_gWIjqfFW1A83q6zu_RatcpXf1Zv4CTOmH8Q
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=PHARMACEUTICAL+DOSAGE+FORM+FOR+ORAL+ADMINISTRATION+OF+A+BCL-2+FAMILY+INHIBITOR&rft.inventor=Knobloch+Martin&rft.inventor=Packhaeuser+Claudia&rft.inventor=Liepold+Bernd&rft.inventor=Kostelac+Drazen&rft.inventor=Steiger+Norbert&rft.date=2017-07-06&rft.externalDBID=A1&rft.externalDocID=US2017189426A1